A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline

Newton, Thomas F.; Garza, Richard De La; Fong, Tim; Chiang, Nora; Holmes, Tyson H.; Blöch, D.; Anderson, Adrianne; Elkashef, Ahmed

doi:10.1016/j.pbb.2005.11.012

Cited by 18 publications

(18 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even less is known about these effects with the intravenous formulation of methamphetamine administered in the human laboratory. The present study establishes the hemodynamic and cardiovascular effects and safety of experimenter-administered intravenous methamphetamine, thereby building upon other human laboratory data (Newton et al, 2005a(Newton et al, , 2005b. Notably, the administration of intravenous methamphetamine doses of up to 30 mg under controlled human laboratory conditions to methamphetamine addicts appears to be safe and only associated with prototypical increases in hemodynamic response.…”

Section: Discussionsupporting

confidence: 56%

Kinetic and cardiovascular effects of acute topiramate dosing among non-treatment-seeking, methamphetamine-dependent individuals

Johnson

Wells

Roache

et al. 2007

Progress in Neuro-Psychopharmacology and Biological Psychiatry

View full text Add to dashboard Cite

Previously, we have shown that orally administered topiramate, a sulfamate-substituted fructopyranose derivative, appears to accentuate rather than diminish some aspects of methamphetamine-induced positive subjective mood and cognitive performance. One possible mechanism by which this might occur would be for topiramate to increase plasma methamphetamine level. Such an effect also would be expected to enhance methamphetamine-induced hemodynamic response. We, therefore, studied -in the same experiment from which the previous findings originated -the effects of topiramate on the kinetic profile and hemodynamic response to methamphetamine. In a 27-day inpatient study, 10 methamphetamine-dependent individuals participated in a double-blind, placebo-controlled, cross-over design, with oral doses of topiramate (0, 100, and 200 mg) administered as a pretreatment before intravenous doses of methamphetamine (0, 15, and 30 mg). The 3 × 3 factorial combination of topiramate and methamphetamine resulted in a sequence of the nine treatments administered to each subject in an order determined by a 9 × 9 Latin Square design. Methamphetamine alone was associated with prototypical increases in hemodynamic response that were not altered in the presence of topiramate. While there was no significant kinetic interaction between topiramate and methamphetamine, there was a non-significant trend for topiramate to increase plasma methamphetamine level. No significant adverse events were reported. The combination of topiramate and methamphetamine at pharmacologically relevant doses appears to be safe. Larger laboratory studies with chronic dosing regimens are needed to establish whether or not there is a kinetic interaction between topiramate and methamphetamine.

show abstract

Section: Discussionsupporting

confidence: 56%

Kinetic and cardiovascular effects of acute topiramate dosing among non-treatment-seeking, methamphetamine-dependent individuals

Johnson

Wells

Roache

et al. 2007

Progress in Neuro-Psychopharmacology and Biological Psychiatry

View full text Add to dashboard Cite

show abstract

“…By comparison, peak effects produced by intranasal, smoked, and i.v. methamphetamine occur within 15 min (Harris et al, 2003;Newton et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

“…By comparison, peak effects produced by intranasal, smoked, and i.v. methamphetamine occur within 15 min (Harris et al, 2003;Newton et al, 2005).Given that the rapidity of drug-related effects is a critical determinant of abuse liability (Hatsukami and Fischman, 1996), it is surprising that only a few studies have examined methamphetamine-related effects via routes of administration other than oral (eg Cook et al, 1993;Mendelson et al, 1995;Newton et al, 2006). Although inhalation by smoking has been increasing in popularity in some cities in the western portion of the United States (Community Epidemiology Work Group, 2005), nasal insufflation appears to be the route of administration with which many individuals first experience problems related to excessive methamphetamine use.…”

mentioning

confidence: 99%

Acute Physiological and Behavioral Effects of Intranasal Methamphetamine in Humans

Hart

Gunderson

Perez

et al. 2007

Neuropsychopharmacol

113

View full text Add to dashboard Cite

Intranasal methamphetamine abuse has increased dramatically in the past decade, yet only one published study has investigated its acute effects under controlled laboratory conditions. Thus, the current study examined the effects of single-dose intranasal methamphetamine administration on a broad range of behavioral and physiological measures. Eleven nontreatment-seeking methamphetamine abusers (two females, nine males) completed this four-session, in-patient, within-participant, double-blind study. During each session, one of four intranasal methamphetamine doses (0, 12, 25, and 50 mg/70 kg) was administered and methamphetamine plasma concentrations, cardiovascular, subjective, and psychomotor/cognitive performance effects were assessed before drug administration and repeatedly thereafter. Following drug administration, methamphetamine plasma concentrations systematically increased for 4 h postdrug administration then declined. Methamphetamine dose dependently increased cardiovascular measures and 'positive' subjective effects, with peaks occurring approximately 5-15 min after drug administration, when plasma levels were still ascending. In addition, cognitive performance on less complicated tasks was improved by all active methamphetamine doses, whereas performance on more complicated tasks was improved only by the intermediate doses (12 and 25 mg). These results show that intranasal methamphetamine produced predictable effects on multiple behavioral and physiological measures before peak plasma levels were observed. Of interest is the dissociation between methamphetamine plasma concentrations with cardiovascular measures and positive subjective effects, which might have important implications for potential toxicity after repeated doses. INTRODUCTIONAlthough methamphetamine abuse has increased dramatically over the past decade, much of our knowledge about its acute effects in humans is anecdotal. The drug is frequently abused via the intranasal, i.v., and smoked routes (Domier et al, 2000; Community Epidemiology Work Group, 2005), but few studies have evaluated the acute effects of methamphetamine in humans using these routes of administration. The majority of studies conducted with humans have focused primarily on the cardiovascular and subjective effects produced by oral methamphetamine, a route of administration least often associated with abuse presumably due to its slow onset of effects. The onset of peak effects produced by oral methamphetamine does not occur until about 90 min after the administration (Hart et al, 2001a). By comparison, peak effects produced by intranasal, smoked, and i.v. methamphetamine occur within 15 min (Harris et al, 2003;Newton et al, 2005).Given that the rapidity of drug-related effects is a critical determinant of abuse liability (Hatsukami and Fischman, 1996), it is surprising that only a few studies have examined methamphetamine-related effects via routes of administration other than oral (eg Cook et al, 1993;Mendelson et al, 1995;Newton et al, 2006). Although inhalation by s...

show abstract

“…Methamphetamine is an indirect agonist of dopamine that promotes the release of monoamine neurotransmitter [22][23]. One of the most important ways is to promote the reverse transport of dopamine and block the dopamine reabsorption [24].…”

Section: Mechanisms Of Psychiatric Diseasementioning

confidence: 99%

Nanomedicine: A New Approach for Treatment Neuropsychiatric Diseases

Wang¹,

Xue²

2017

View full text Add to dashboard Cite

Abstract:Nervous system diseases, such as Alzheimer's disease, stroke, and Parkinson's disease, are spreading around the world. These diseases involve complicatedly pathological processes, and so far, there are no effective medicines for therapy. Another type of psychiatric disorder is induced by drugs. The synthetic drugs, represented by methamphetamine, are becoming widely abuse. At present, the cure of methamphetamine dependence is mainly symptomatic treatment, but the recurrence rate is very high. As the common brain impairments in neuropsychiatric disease, it is necessary to summary novel strategies effectively restored brain function. In recent years, carbon nanotubes have attracted the attention due to their unique properties in the field of translational medicine. Recently, new advances reported that carbon nanotubes as a nanomedicine to treat various neuropsychiatric disorders. The purpose of this review is to introduce the therapeutic approaches and mechanisms of carbon nanotubes on neuropsychiatric disorders.

show abstract

A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline

Cited by 18 publications

References 21 publications

Kinetic and cardiovascular effects of acute topiramate dosing among non-treatment-seeking, methamphetamine-dependent individuals

Kinetic and cardiovascular effects of acute topiramate dosing among non-treatment-seeking, methamphetamine-dependent individuals

Acute Physiological and Behavioral Effects of Intranasal Methamphetamine in Humans

Nanomedicine: A New Approach for Treatment Neuropsychiatric Diseases

Contact Info

Product

Resources

About